# Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

> **NCT01193595** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 39 (actual)

## Conditions studied

- Neoplasms, Malignant

## Interventions

- **DRUG:** Ombrabulin (AVE8062)
- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT01193595
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193595

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193595, "Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01193595. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*